Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Barratt

Showing results (51-60 of 272) with videos related to

Pageof 28
Sort By:
Frontiers in Medicine|August 30, 2024
Therapy of IgA nephropathy: time for a paradigm changeJonathan Barratt, Richard A Lafayette, Jürgen Floege
Nephrology (Carlton, Vic.)|May 15, 2007
The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathyJonathan Barratt, Alice C Smith, John Feehally
The New England Journal of Medicine|May 14, 2025
Alternative Complement Pathway, Iptacopan, and IgA Nephropathy. ReplyJonathan Barratt, Vlado Perkovic, Dana V Rizk
Current Opinion in Nephrology and Hypertension|March 3, 2023
An update on corticosteroid treatment for IgA nephropathyMalak Ghaddar, Jonathan Barratt, Sean J Barbour
Kidney International Reports|February 12, 2024
Novel Treatment Paradigms: Primary IgA NephropathyHaresh Selvaskandan, Jonathan Barratt, Chee Kay Cheung
Nephrology (Carlton, Vic.)|April 13, 2019
Is immunoglobulin A nephropathy different in different ethnic populations?See Cheng Yeo, Su Mein Goh, Jonathan Barratt
Lancet (London, England)|December 20, 2017
Targeted-release budesonide therapy for IgA nephropathy - Authors' replyBengt Fellström, Jonathan Barratt, Jürgen Flöge, et al.
Drug Design, Development and Therapy|August 5, 2024
Insights on Nefecon<sup>®</sup>, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA NephropathyJonathan Barratt, Jens Kristensen, Christian Pedersen, et al.
Current Opinion in Nephrology and Hypertension|July 22, 2025
IgA nephropathy: a paradigm shift in treatment strategiesLydia Roberts, Max Jones, Jonathan Barratt, et al.
Journal of Clinical Medicine|June 2, 2021
The Non-Coding RNA Landscape in IgA Nephropathy-Where Are We in 2021?Izabella Z A Pawluczyk, Haresh Selvaskandan, Jonathan Barratt
Pageof 28

Showing results (51-60 of 272) with videos related to

Sort By:
Pageof 28
Frontiers in Medicine|August 30, 2024
Therapy of IgA nephropathy: time for a paradigm changeJonathan Barratt, Richard A Lafayette, Jürgen Floege
Nephrology (Carlton, Vic.)|May 15, 2007
The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathyJonathan Barratt, Alice C Smith, John Feehally
The New England Journal of Medicine|May 14, 2025
Alternative Complement Pathway, Iptacopan, and IgA Nephropathy. ReplyJonathan Barratt, Vlado Perkovic, Dana V Rizk
Current Opinion in Nephrology and Hypertension|March 3, 2023
An update on corticosteroid treatment for IgA nephropathyMalak Ghaddar, Jonathan Barratt, Sean J Barbour
Kidney International Reports|February 12, 2024
Novel Treatment Paradigms: Primary IgA NephropathyHaresh Selvaskandan, Jonathan Barratt, Chee Kay Cheung
Nephrology (Carlton, Vic.)|April 13, 2019
Is immunoglobulin A nephropathy different in different ethnic populations?See Cheng Yeo, Su Mein Goh, Jonathan Barratt
Lancet (London, England)|December 20, 2017
Targeted-release budesonide therapy for IgA nephropathy - Authors' replyBengt Fellström, Jonathan Barratt, Jürgen Flöge, et al.
Drug Design, Development and Therapy|August 5, 2024
Insights on Nefecon<sup>®</sup>, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA NephropathyJonathan Barratt, Jens Kristensen, Christian Pedersen, et al.
Current Opinion in Nephrology and Hypertension|July 22, 2025
IgA nephropathy: a paradigm shift in treatment strategiesLydia Roberts, Max Jones, Jonathan Barratt, et al.
Journal of Clinical Medicine|June 2, 2021
The Non-Coding RNA Landscape in IgA Nephropathy-Where Are We in 2021?Izabella Z A Pawluczyk, Haresh Selvaskandan, Jonathan Barratt
Pageof 28